Edison Oncology Holding Corp. (EOHC)
| Market Cap | 74.79M |
| Revenue (ttm) | 446,091 -21.7% |
| Net Income | -4.64M |
| EPS | -0.56 |
| Shares Out | 8.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EOHC
Edison Oncology is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies for cancer by unlocking the potential of existing drugs and compounds. We seek to make meaningful improvements through strategic reformulation and / or repurposing using a modernized understanding of their mechanisms of action to address significant unmet medical needs. Our development strategy prioritizes product candidates that may qualify for accelerated marketing approval under the U.S. Food and Drug Administration’s exped... [Read more]
Financial Performance
Financial StatementsNews
Edison Oncology IPO Registration Document (S-1)
Edison Oncology has filed to go public with an IPO on the NYSE American.
Phase 2 oncology biotech Edison Oncology Holding files and sets terms for a $25 million IPO
Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, filed on Friday with the SEC to raise up to $25 million in an initial public offering.